Squarepoint
BCRX icon

Squarepoint’s BioCryst Pharmaceuticals BCRX Stock Holding History

Squarepoint’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-49,500
Closed -$372K – 4581
2024
Q4 		$372K Buy
+49,500
New +$376K ﹤0.01% 3992

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Squarepoint's BCRX Position: Q1 2026 in Review

Squarepoint reduced its BioCryst Pharmaceuticals (BCRX) stake by 98% in Q1 2026, selling an estimated $12.6M and leaving 39,765 shares worth $379K. The position accounts for ﹤0.01% of the portfolio, ranked #3533.

Squarepoint first reported a position in BCRX in Q4 2015 and has held it in 34 quarters since. The position peaked at $12.9M in Q4 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Squarepoint held 39,765 shares of BioCryst Pharmaceuticals worth $379K as of Q1 2026.
  • Squarepoint sold 1,619,427 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $12.6M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3533 holding.
  • Squarepoint first reported a position in BioCryst Pharmaceuticals in Q4 2015 and has held it in 34 quarters since.
  • Squarepoint's BioCryst Pharmaceuticals position peaked at $12.9M in Q4 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.